You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The San Diego firm has now raised at least $145 million to drive development of its DNA sequencing platform and build manufacturing and commercial operations.
The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.
The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.
The University of Washington spinout will use the funding to commercialize duplex sequencing technology to detect low-frequency DNA mutations.
The UK-based sequencing technology firm raised £29.3 million in capital and sold £80.2 million in secondary shares.
The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.
The firm did an initial close of its Series A financing round and will pursue additional investments during Q1 2020 when the round is anticipated to close.
The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.
The company said that it plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications.
Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.